Status:
COMPLETED
A Trial In Patients With Advanced Cancer And Leukemia
Lead Sponsor:
Pfizer
Conditions:
Neoplasms by Histologic Type
Eligibility:
All Genders
16+ years
Phase:
PHASE1
Brief Summary
This is a phase 1, dose escalating study to determine the safety of PF-03084014 in patients with advanced cancer and leukemia
Eligibility Criteria
Inclusion
- Patients with advanced cancer that is resistant to standard therapy or for which no standard therapy is available
- Patients with acute T cell leukemia/lymphoblastic lymphoma that is resistant to standard therapy or for which no standard therapy is available
- Men and women \>16 years old
Exclusion
- Prior treatment with a gamma secretase inhibitor for treatment of cancer
- Patients taking Tamoxifen
- Patients with active graft versus host disease
- Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness
- Patients who are pregnant or breast feeding
- Patients with clinical evidence of central nervous system disease
Key Trial Info
Start Date :
June 25 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 22 2016
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT00878189
Start Date
June 25 2009
End Date
November 22 2016
Last Update
November 12 2019
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Anschutz Cancer Pavilion
Aurora, Colorado, United States, 80045
2
University of Colorado Denver CTRC
Aurora, Colorado, United States, 80045
3
University of Colorado Hospital
Aurora, Colorado, United States, 80045
4
Massachusetts General Hospital Clinical Laboratory
Boston, Massachusetts, United States, 02114